Anna Man Wu

US Patent:

6410319, Jun 25, 2002

Filed:

Oct 20, 1999

Appl. No.:

09/421295

Inventors:

Andrew Raubitschek - San Marino CA
Anna Wu - Sherman Oaks CA
Michael C. Jensen - Pasadena CA

Assignee:

City of Hope - Duarte CA

International Classification:

C12N 506

US Classification:

4353431, 4353201, 435325, 435326, 435328, 435332, 435343, 435344, 435372, 4353722, 4353723, 536 231, 536 234

Abstract:

Genetically engineered, CD20-specific redirected T cells expressing a cell surface protein-having an extracellular domain comprising a receptor which is specific for CD20, an intracellular signaling domain, and a transmembrane domain. Use of such cells for cellular immunotherapy of CD20 malignancies and for abrogating any untoward B cell function. In one embodiment, the cell surface protein is a single chain FvFc: receptor where Fv designates the V and V chains of a single chain monoclonal antibody to CD20 linked by peptide, Fc represents a hinge-CH -CH region of a human IgG , and represents the intracellular signaling domain of the zeta chain of human CD3. A method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.

US Patent:

7273608, Sep 25, 2007

Filed:

Mar 11, 2005

Appl. No.:

11/077978

Inventors:

Paul J. Yazaki - Glendale CA, US
Mark A. Sherman - Pasadena CA, US
John E. Shively - Arcadia CA, US
Andrew A. Raubitschek - San Marino CA, US
Anna M. Wu - Sherman Oaks CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

A61K 39/00

US Classification:

4241331

Abstract:

Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84. 66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84. 66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84. 66 and the ability to specifically target tumors expressing CEA in vivo.

US Patent:

7727525, Jun 1, 2010

Filed:

Apr 27, 2007

Appl. No.:

11/741253

Inventors:

Anna M. Wu - Sherman Oaks CA, US
Tove Olafsen - Sherman Oaks CA, US
Andrew A. Raubitschek - San Marino CA, US

Assignee:

City of Hope - Duarte CA
The Regents of the University of California - Oakland CA

International Classification:

A61K 51/10
A61K 49/00
A61K 39/395

US Classification:

4241331, 424 149, 424 91, 4241441, 4241551, 4241741, 4241731, 5303877, 5303887, 53038873, 5303888

Abstract:

The present invention provides anti-CD20 antibody fragments for use as in vivo imaging probes and as therapeutic moieties for the diagnosis and treatment of NHL.

US Patent:

7776330, Aug 17, 2010

Filed:

Sep 25, 2007

Appl. No.:

11/861093

Inventors:

Paul J. Yazaki - Glendale CA, US
Mark A. Sherman - Pasadena CA, US
John E. Shively - Arcadia CA, US
Andrew A. Raubitschek - San Marino CA, US
Anna M. Wu - Sherman Oaks CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

A61K 39/395
C12P 21/04
C12P 21/08
C07K 16/00

US Classification:

4241331, 4241411, 4241561, 4241811, 4241831, 435 696, 435 7021, 5303873, 5303881, 53038885, 5303917

Abstract:

Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84. 66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84. 66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84. 66 and the ability to specifically target tumors expressing CEA in vivo.

US Patent:

8088908, Jan 3, 2012

Filed:

May 10, 2006

Appl. No.:

11/432304

Inventors:

Mark A. Sherman - Pasadena CA, US
Anna M. Wu - Sherman Oaks CA, US
Robert E. Reiter - Los Angeles CA, US

Assignee:

City of Hope - Duarte CA
The Regents of the University of California - Oakland CA

International Classification:

C07H 21/04

US Classification:

536 2353, 536 231

Abstract:

Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.

US Patent:

8318906, Nov 27, 2012

Filed:

Oct 8, 2008

Appl. No.:

12/682032

Inventors:

Jonathan Braun - Tarzana CA, US
Lynn K. Gordon - Tarzana CA, US
Kaori Shimizaki - Los Angeles CA, US
Kathy A. Kelly - Sherman Oaks CA, US
Anna M. Wu - Sherman Oaks CA, US

Assignee:

The Regents of The University of California - Oakland CA

International Classification:

C07K 16/00
C12P 21/08
A61K 39/395
G01N 33/566

US Classification:

5303871, 4241581, 436501, 5303873, 5303881, 5303892

Abstract:

The present invention provides methods and compositions useful in the treatment or prevention of infections and cancer. The methods and compositions inhibit the entry of into a host cell expressing EMP2 by interfering with the interaction between the and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.

US Patent:

8404817, Mar 26, 2013

Filed:

Dec 1, 2011

Appl. No.:

13/308783

Inventors:

Mark A. Sherman - Pasadena CA, US
Anna M. Wu - Sherman Oaks CA, US
Robert E. Reiter - Los Angeles CA, US

Assignee:

City of Hope - Duarte CA
The Regents of the University of California - Oakland CA

International Classification:

C12P 21/08

US Classification:

5303873, 5303911, 5303913, 5303917

Abstract:

Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.

US Patent:

8043830, Oct 25, 2011

Filed:

Jan 30, 2009

Appl. No.:

12/363678

Inventors:

Bhaswati Barat - Los Angeles CA, US
Anna M. Wu - Sherman Oaks CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12P 21/00
C12P 21/04

US Classification:

435 691, 435 697

Abstract:

The present invention provides methods of metabolically biotinylating recombinant proteins. Cell lines and specific protein and nucleic acid constructs for use in the methods of the present invention are also provided herein.